Article
Oncology
Tiantian Wang, Jie Tang, Hongying Yang, Rutie Yin, Jingru Zhang, Qi Zhou, Ziling Liu, Lanqin Cao, Li Li, Yi Huang, Kui Jiang, Wei Wang, Fenglin She, Ni Guan, Zhiguo Hou, Ning Li, Lingying Wu
Summary: This study evaluated the efficacy and safety of apatinib plus PLD in treating patients with PROC. The results showed promising efficacy and manageable toxic effects in PROC patients treated with apatinib plus PLD.
Article
Reproductive Biology
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Summary: This study evaluated the efficacy and safety of PLD in treating platinum-resistant and platinum-refractory relapse in patients with epithelial ovarian, fallopian tube, and peritoneal cancer. The results showed that PLD was associated with satisfactory efficacy, low frequency of adverse events, and high patient quality of life, with low baseline CA125 levels and a reduction in CA125 after the first cycle predicting satisfactory efficacy.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Reproductive Biology
Xin-Ru Li, Yi Zhu, Guo-Nan Zhang, Jian-Ming Huang, Li-Xia Pei
Summary: This study found through meta-analysis that in recurrent ovarian cancer, pegylated liposomal doxorubicin plus carboplatin was more effective than paclitaxel plus carboplatin, while pegylated liposomal doxorubicin monotherapy showed similar survival outcomes to other monotherapies. Both treatment regimens were well tolerated in terms of side effects.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, Emanuele Naglieri, Mikel Arruti Ibarbia, Federica Brusa, Hugues Bourgeois, Roberto Sorio, Antonio Casado, Dietmar Reichert, Catherine Dopchie, Beatriz De Rivas, Luis Miguel de Sande
Summary: The study showed that the combination of trabectedin/PLD is a clinically meaningful and safe option for patients with platinum-sensitive recurrent ovarian cancer, regardless of prior treatment with an antiangiogenic drug. Patients overall had good survival outcomes and clinical benefits.
Article
Oncology
Katherine C. Fuh, Michael A. Bookman, Joyce F. Liu, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Bradley J. Monk, Randy Anderson, Gail McIntyre, Reshma Rangwala, Kathleen N. Moore
Summary: AVB-500, a novel high affinity Fc-sAXL fusion protein, combined with chemotherapy showed promising clinical activity in platinum-resistant ovarian cancer (PROC) patients, with no dose limiting toxicities observed.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Reproductive Biology
Xin-Ru Li, Xing-Han Cheng, Guo-Nan Zhang, Xiao-Xin Wang, Jian-Ming Huang
Summary: This study summarizes the high-risk factors, clinical dose thresholds, and cardiac function testing modalities for PLD-induced cardiotoxicity, providing guidance for its clinical use.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Oncology
Konstantin Schlick, Dominik Kiem, Florian Huemer, Daniel Neureiter, Lukas Weiss, Richard Greil
Summary: A retrospective analysis of 28 pancreatic cancer patients treated with nonpegylated liposomal doxorubicin between 2012 and 2018 showed limited benefit of the drug beyond the second line of therapy.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Oncology
Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang, Xi Wang
Summary: In neoadjuvant and adjuvant treatment of breast cancer, Pegylated liposomal doxorubicin (PLD) showed similar effectiveness but different toxicities compared to epirubicin. PLD was found to be non-inferior to epirubicin in adjuvant chemotherapy for breast cancer, with lower rates of certain adverse reactions. Further studies are needed to explore the use of PLD-based chemotherapy for breast cancer.
Article
Oncology
Takuma Ooyama, Yuko Shimoji, Tadaharu Nakasone, Yoshihisa Arakaki, Yusuke Taira, Tomoko Nakamoto, Wataru Kudaka, Yoichi Aoki
Summary: Pegylated liposomal doxorubicin (PLD) has a high disease control rate (DCR) in the treatment of recurrent ovarian cancer, and the treatment effect can be predicted by the reduction of CA125 level after 2 courses.
ANTICANCER RESEARCH
(2022)
Article
Genetics & Heredity
Wenxian Hu, Kezhen Lv, Rongyue Teng, Jida Chen, Chenpu Xu, Lidan Jin, Yongxia Chen, Wenhe Zhao
Summary: This retrospective study comparing PLD and epirubicin as adjuvant therapy for breast cancer found that PLD has similar anti-cancer efficacy as epirubicin while inducing lower levels of cardiac toxicity in Han Chinese population. The study suggests that PLD-based adjuvant chemotherapy could be a better option than epirubicin for breast cancer patients, especially those with existing cardiac diseases.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Takashi Motohashi, Akira Yabuno, Hiroshi Michimae, Tetsuro Ohishi, Miwa Nonaka, Masashi Takano, Shin Nishio, Hiroyuki Fujiwara, Keiichi Fujiwara, Eiji Kondo, Toru Sugiyama, Tsutomu Tabata
Summary: This study compared the efficacy of 40mg/m2 and 50mg/m2 pegylated liposomal doxorubicin in treating platinum-resistant ovarian carcinoma patients, and found no significant difference in PFS and OS between the two doses. However, the standard dose group experienced more hematologic toxicity and oral cavity mucositis.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Hiroyuki Yoshida, Keiichi Fujiwara
Summary: This study evaluated the relationship between adipose tissue status and the efficacy of PLD. It was found that patients with a high visceral to subcutaneous adipose tissue area ratio (VSR) had a poor response to PLD and shorter progression-free survival (PFS). Thus, VSR is an important predictive biomarker for the efficacy of PLD.
Article
Obstetrics & Gynecology
Yoshifumi Takahashi, Yuji Takei, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Takahiro Yoshiba, Takahiro Koyanagi, Kohei Tamura, Yasushi Saga, Hiroyuki Fujiwara
Summary: This study retrospectively reviewed the medical records of 78 patients with platinum-resistant recurrent ovarian cancer who underwent PLD therapy, finding that the DCR did not decrease with a greater number of previous regimens, and when the number of previous regimens was 3 or higher, PLD therapy had a superior DCR to GEM therapy.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
(2021)
Article
Oncology
Alessia Anastasia, Giulia Dellavedova, Antonio Ramos-Montoya, Neil James, Giovanna Chiorino, Massimo Russo, Hana Baakza, Joanne Wilson, Carmen Ghilardi, Elaine B. Cadogan, Raffaella Giavazzi, Maria Rosa Bani
Summary: The DNA-PK inhibitor AZD7648, when administered in combination with pegylated liposomal doxorubicin (PLD) or the PARP inhibitor olaparib, shows promising efficacy in delaying disease progression and inhibiting tumor growth and metastasis in ovarian cancer. The combination therapy enhances the therapeutic effect of PLD and olaparib, especially in BRCA-deficient patients.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi
Summary: The study compared the efficacy and safety of nivolumab versus chemotherapy in patients with platinum-resistant ovarian cancer, and found that although nivolumab was well-tolerated, it did not improve overall survival and showed worse progression-free survival compared to chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Immunology
Annette H. Sohn, Stephen J. Kerr, Rawiwan Hansudewechakul, Sivaporn Gatechompol, Kulkanya Chokephaibulkit, Hanh Le Dung Dang, Dan Ngoc Hanh Tran, Jullapong Achalapong, Nipat Teeratakulpisarn, Amphan Chalermchockcharoenkit, Manopchai Thamkhantho, Tippawan Pankam, Thida Singtoroj, Wichai Termrungruanglert, Surasith Chaithongwongwatthana, Nittaya Phanuphak
CLINICAL INFECTIOUS DISEASES
(2018)
Meeting Abstract
Economics
W. Termrungruanglert, N. Khemapech, P. Havanond, M. Pillsbury, A. Shcheprov, K. Numuang, A. Kulkarni
Article
Obstetrics & Gynecology
Pattiya Nutthachote, Shina Oranratanaphan, Wichai Termrungruanglert, Surang Triratanachat, Arkom Chaiwongkot, Fern Baedyananda, Parvapan Bhattarakosol
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY
(2019)
Article
Immunology
Nittaya Phanuphak, Sirinya Teeraananchai, Rawiwan Hansudewechakul, Sivaporn Gatechompol, Kulkanya Chokephaibulkit, Hanh Le Dung Dang, Dan Ngoc Hanh Tran, Jullapong Achalapong, Nipat Teeratakulpisarn, Amphan Chalermchockcharoenkit, Manopchai Thamkhantho, Tippawan Pankam, Thida Singtoroj, Wichai Termrungruanglert, Surasith Chaithongwongwatthana, Stephen J. Kerr, Annette H. Sohn
CLINICAL INFECTIOUS DISEASES
(2020)
Article
Multidisciplinary Sciences
Wichai Termrungruanglert, Nipon Khemapech, Apichai Vasuratna, Piyalamporn Havanond, Preyanuch Deebukkham, Amit Sharad Kulkarni, Andrew Pavelyev
Summary: The study assessed the epidemiological consequences and cost-effectiveness of routine quadrivalent HPV vaccination and catch-up vaccination in Thailand, compared to cervical cancer screening only. Results showed that both vaccination strategies were cost-effective in preventing cervical cancer and HPV-related diseases over 100 years, with estimated cost per QALY gained of 8,370 THB for routine vaccination and 9,650 THB for routine with catch-up vaccination.
Article
Oncology
Tanitra Tantitamit, Nipon Khemapech, Piyalamporn Havanond, Wichai Termrungruanglert
Article
Oncology
Eiko Saitoh Aoki, Rutie Yin, Kemin Li, Neerja Bhatla, Seema Singhal, Dwiana Ocviyanti, Kumiko Saika, Mina Suh, Miseon Kim, Wichai Termrungruanglert
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Wichai Termrungruanglert, Nipon Khemapech, Tanitra Tantitamit, Piyalamporn Havanond
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2019)
Article
Obstetrics & Gynecology
Shina Oranratanaphan, Sinee Wanishpongpan, Wichai Termrungruanglert, Surang Triratanachat
OBSTETRICS AND GYNECOLOGY INTERNATIONAL
(2018)
Article
Obstetrics & Gynecology
Wichai Termrungruanglert, Nipon Khemapech, Tanitra Tantitamit, Suleeporn Sangrajrang, Piyalamporn Havanond, Piyawat Laowahutanont
GYNECOLOGIC ONCOLOGY REPORTS
(2017)
Meeting Abstract
Immunology
S. Sricharoenchai, T. Bunupuradah, R. Hansudewechakul, D. L. D. Hanh, D. N. H. Tran, S. Kerr, A. Chalermchockcharoenkit, N. Teeratakulpisarn, J. Achalapong, D. N. Y. Dung, W. Termrungruanglert, S. Chaithongwongwatthana, T. Singtoroj, T. Pankam, N. Phanuphak, A. H. Sohn, K. Chokephaibulkit
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2017)
Meeting Abstract
Oncology
T. Manchana, N. Sirisabya, P. Worasethsin, A. Vasuratna, W. Termrungruanglert, D. Tresukosol
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2015)
Meeting Abstract
Oncology
T. Tantitamit, W. Termrungruanglert, S. Oranratanaphan, S. Niruthisard, P. Tanbirojn, P. Havanond
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2014)
Meeting Abstract
Oncology
W. Termrungruanglert, N. Khemapech, P. Havanond, M. Pillsbury, A. Shcheprov, K. Numuang, E. Metharom, A. Kulkarni
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2014)
Meeting Abstract
Oncology
S. Oranratanaphan, W. Termrungruanglert, N. Khemapech
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2014)